Newsroom | 5 results

SAO SAO--(BUSINESS WIRE)--Elit nulla dictum volutpat phasellus facilisi quam luctus sem montes aptent iaculis auctor ac, placerat purus litora commodo molestie posuere phasellus. Hendrerit eleifend. Purus neque pharetra. Iaculis lacus pede mollis natoque. Rutrum penatibus risus, fermentum malesuada tempus consectetuer magnis placerat libero dictumst nascetur augue ullamcorper dis. Risus amet porttitor lorem ultricies sociosqu quisque convallis tempor ridiculus inceptos volutpat blandit lacus ip...

SAO SAO--(BUSINESS WIRE)--Elit nulla dictum volutpat phasellus facilisi quam luctus sem montes aptent iaculis auctor ac, placerat purus litora commodo molestie posuere phasellus. Hendrerit eleifend. Purus neque pharetra. Iaculis lacus pede mollis natoque. Rutrum penatibus risus, fermentum malesuada tempus consectetuer magnis placerat libero dictumst nascetur augue ullamcorper dis. Risus amet porttitor lorem ultricies sociosqu quisque convallis tempor ridiculus inceptos volutpat blandit lacus ip...

BOSTON & GAITHERSBURG, Md.--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Deneen Vojta, M.D. to its Board of Directors. Dr. Vojta brings over 25 years of experience in business development, entrepreneurship and health systems. “Dr. Vojta is a significant addition to our Board of Directors at an important time for Sensei and we are thrill...

IRVING, TX--(BUSINESS WIRE)--HappyTests Corporation today announced the launch of Testprod, an oncology technology and insights business designed to support innovation, acceleration, and evidence generation to drive better outcomes for patients with cancer. “Testprod reflects HappyTests’s continued commitment and investment in the oncology community,” said Twill Test III, chief executive officer, HappyTests. “As one of the largest healthcare companies, HappyTests is at the center of care delive...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, will be presented at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) being held in Vienna, December 4 to 7, 2016. “We are excited that updated data from the ALTA trial on brigatinib in pa...